WINTON GROUP Ltd Sells 5,240 Shares of Boston Scientific Co. (NYSE:BSX)

WINTON GROUP Ltd decreased its position in shares of Boston Scientific Co. (NYSE:BSX) by 8.5% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 56,146 shares of the medical equipment provider’s stock after selling 5,240 shares during the period. WINTON GROUP Ltd’s holdings in Boston Scientific were worth $5,015,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in BSX. Kingsview Wealth Management LLC boosted its stake in Boston Scientific by 5.0% in the third quarter. Kingsview Wealth Management LLC now owns 5,970 shares of the medical equipment provider’s stock worth $500,000 after buying an additional 282 shares in the last quarter. Truvestments Capital LLC bought a new stake in shares of Boston Scientific in the 3rd quarter worth approximately $49,000. The Manufacturers Life Insurance Company boosted its stake in shares of Boston Scientific by 1.8% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 1,120,466 shares of the medical equipment provider’s stock valued at $93,895,000 after purchasing an additional 20,330 shares in the last quarter. D.A. Davidson & CO. grew its holdings in shares of Boston Scientific by 3.2% during the 3rd quarter. D.A. Davidson & CO. now owns 10,945 shares of the medical equipment provider’s stock valued at $917,000 after purchasing an additional 342 shares during the last quarter. Finally, Avestar Capital LLC raised its position in Boston Scientific by 10.3% in the 3rd quarter. Avestar Capital LLC now owns 12,397 shares of the medical equipment provider’s stock worth $1,039,000 after purchasing an additional 1,158 shares during the period. Institutional investors own 89.07% of the company’s stock.

Analysts Set New Price Targets

BSX has been the subject of several analyst reports. Barclays upped their price target on shares of Boston Scientific from $111.00 to $118.00 and gave the company an “overweight” rating in a research report on Monday, February 10th. UBS Group increased their target price on Boston Scientific from $105.00 to $130.00 and gave the company a “buy” rating in a report on Friday, February 7th. Deutsche Bank Aktiengesellschaft raised Boston Scientific from a “hold” rating to a “buy” rating and set a $108.00 price target on the stock in a research note on Friday, January 10th. Stifel Nicolaus increased their price objective on Boston Scientific from $100.00 to $115.00 and gave the company a “buy” rating in a research note on Thursday, February 6th. Finally, StockNews.com downgraded shares of Boston Scientific from a “buy” rating to a “hold” rating in a research note on Saturday, March 8th. Two investment analysts have rated the stock with a hold rating, twenty-one have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Boston Scientific presently has a consensus rating of “Moderate Buy” and a consensus target price of $108.91.

Insider Activity at Boston Scientific

In other Boston Scientific news, EVP John Bradley Sorenson sold 4,119 shares of the firm’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $90.02, for a total transaction of $370,792.38. Following the completion of the transaction, the executive vice president now owns 35,319 shares of the company’s stock, valued at approximately $3,179,416.38. This trade represents a 10.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Jeffrey B. Mirviss sold 4,675 shares of the business’s stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $104.25, for a total value of $487,368.75. Following the completion of the sale, the executive vice president now directly owns 28,454 shares in the company, valued at approximately $2,966,329.50. This represents a 14.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 137,302 shares of company stock valued at $14,319,269 in the last three months. Company insiders own 0.50% of the company’s stock.

Boston Scientific Stock Down 0.7 %

Shares of NYSE:BSX opened at $102.31 on Thursday. The firm has a market capitalization of $151.32 billion, a P/E ratio of 81.85, a P/E/G ratio of 2.79 and a beta of 0.77. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.02 and a current ratio of 1.08. The stock has a 50 day moving average price of $102.10 and a 200-day moving average price of $92.87. Boston Scientific Co. has a 52-week low of $66.80 and a 52-week high of $107.17.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. As a group, equities research analysts anticipate that Boston Scientific Co. will post 2.85 EPS for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.